Study of hearing loss in children with GJB2 or OTOF gene changes
Part of Brain & nervous system, Ear, nose & throat clinical trials.
This study follows children with hearing loss caused by changes in specific genes (GJB2 or OTOF). It helps researchers understand how hearing develops over time and how children may do with or without cochlear implants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age is 16 or younger (or 10 or younger for the second group/cohort).
- You have hearing loss in both ears that is not caused by a syndrome (not a syndromic condition).
- Your hearing loss is sensorineural, meaning the inner ear/nerve pathway is affected (not mainly an outer-ear or middle-ear problem).
- Your genetic test shows a mutation in the GJB2 or OTOF gene.
- You have either no cochlear implant or you have one or both cochlear implants.
- You can follow the study visits and procedures, and you/your guardian can provide consent as required.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at hearing loss that starts in early adulthood (after age 16) and is linked to a specific gene change (GJB2). Researchers want to understand how this type of hearing loss changes over time.
This trial tests a gene therapy called EH002 for people with severe or profound hearing loss due to changes in the OTOF gene. The treatment aims to help the ear hear better by replacing the faulty gene.
This study follows people with hearing loss caused by changes (mutations) in the otoferlin gene to better understand how hearing and hearing-related test results change over time. It may help researchers prepare for future treatments by building a clear picture of the natural course of the condition.
This study tests an experimental gene therapy (SKY-GJB2) designed to treat hearing loss caused by mutations in the GJB2 gene. The therapy is given directly to children ages 9 months to 7 years who have significant bilateral hearing loss, and researchers will monitor safety and whether hearing improves.
This early-stage study tests a one-time gene therapy to help patients with profound hearing loss linked to otoferlin gene mutations. It may help hearing by delivering a working version of the otoferlin gene to the inner ear, followed by long-term monitoring.
This trial tests a new bone-anchored hearing system called OSIA for children born with missing or incomplete outer ears (microtia or atresia). It aims to see if the implant works well on both sides for improving hearing.
Hear when a new Sensorineural Hearing Loss, Bilateral trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.